NR1I2 and primary biliary cholangitis: A study investigating the use of bezafibrate, a dual PPAR/PXR agonist, in PBC patients found a significant increase in PXR gene expression after treatment and suggested that this decrease may contribute to the anticholestatic activity of bezafibrate [49].